[go: up one dir, main page]

ECSP055780A - Derivados de indol utiles para el tratamiento de enfermedades - Google Patents

Derivados de indol utiles para el tratamiento de enfermedades

Info

Publication number
ECSP055780A
ECSP055780A EC2005005780A ECSP055780A ECSP055780A EC SP055780 A ECSP055780 A EC SP055780A EC 2005005780 A EC2005005780 A EC 2005005780A EC SP055780 A ECSP055780 A EC SP055780A EC SP055780 A ECSP055780 A EC SP055780A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
derivatives useful
indol derivatives
disorders
Prior art date
Application number
EC2005005780A
Other languages
English (en)
Inventor
Mark Edward Bunnage
Alan Daniel Brown
Justin Stephen Bryans
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Simon John Mantell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020292513 external-priority patent/EP1407769A1/en
Priority claimed from EP03290069A external-priority patent/EP1440966A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP055780A publication Critical patent/ECSP055780A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a derivados de indol y a procedimientos para la preparación de intermedios usados en la preparación de composiciones que los contienen y el uso de dichos derivados. Los derivados de indol según la presente invención son útiles en numerosas enfermedades, trastornos y afecciones, en particular enfermedades, trastornos y afecciones inflamatorias, alérgicas y respiratorias.
EC2005005780A 2002-10-11 2005-05-05 Derivados de indol utiles para el tratamiento de enfermedades ECSP055780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020292513 EP1407769A1 (en) 2002-10-11 2002-10-11 Indole derivatives as beta-2 agonists
EP03290069A EP1440966A1 (en) 2003-01-10 2003-01-10 Indole derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
ECSP055780A true ECSP055780A (es) 2005-08-11

Family

ID=32095049

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005780A ECSP055780A (es) 2002-10-11 2005-05-05 Derivados de indol utiles para el tratamiento de enfermedades

Country Status (25)

Country Link
EP (1) EP1556034B1 (es)
JP (1) JP4490911B2 (es)
KR (1) KR20050047552A (es)
AP (1) AP2005003283A0 (es)
AR (1) AR041566A1 (es)
AT (1) ATE392206T1 (es)
AU (1) AU2003269316A1 (es)
BR (1) BR0315234A (es)
CA (1) CA2499314C (es)
CO (1) CO5550421A2 (es)
DE (1) DE60320439T2 (es)
EA (1) EA200500618A1 (es)
EC (1) ECSP055780A (es)
ES (1) ES2302938T3 (es)
IS (1) IS7751A (es)
MA (1) MA27452A1 (es)
MX (1) MXPA05003866A (es)
NO (1) NO20051406L (es)
OA (1) OA12938A (es)
PA (1) PA8586001A1 (es)
PE (1) PE20040775A1 (es)
PL (1) PL376396A1 (es)
TW (1) TW200424171A (es)
UY (1) UY28013A1 (es)
WO (1) WO2004032921A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
AU2007275931B2 (en) 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
BRPI0721039A2 (pt) 2006-12-19 2014-07-29 Astrazeneca Ab " derivados de quinuclidinol como antagonistas de receptores muscarínicos ".
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2117541A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
CN102089304A (zh) 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
DK2297106T3 (da) 2008-05-27 2014-10-06 Astrazeneca Ab Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
PE20141614A1 (es) 2011-06-10 2014-11-20 Chiesi Farma Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
BR112015012730B1 (pt) 2012-12-06 2022-07-05 Chiesi Farmaceutici S.P.A. Composto, composição farmaceutica, dispositivo, uso de um composto e combinação
RU2661877C2 (ru) 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AR099336A1 (es) 2014-02-17 2016-07-13 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0703911T3 (da) * 1993-06-14 1997-10-06 Pfizer Sekundære aminer som antidiabetiske og antiobesitetsmidler
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US5859044A (en) * 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists

Also Published As

Publication number Publication date
DE60320439T2 (de) 2009-05-20
CA2499314C (en) 2010-08-24
UY28013A1 (es) 2004-04-30
BR0315234A (pt) 2005-08-23
ATE392206T1 (de) 2008-05-15
AR041566A1 (es) 2005-05-18
IS7751A (is) 2005-03-17
PL376396A1 (en) 2005-12-27
JP4490911B2 (ja) 2010-06-30
NO20051406L (no) 2005-04-22
OA12938A (en) 2006-10-13
CO5550421A2 (es) 2005-08-31
KR20050047552A (ko) 2005-05-20
AP2005003283A0 (en) 2005-06-30
ES2302938T3 (es) 2008-08-01
EA200500618A1 (ru) 2005-12-29
JP2006511596A (ja) 2006-04-06
PA8586001A1 (es) 2005-02-04
AU2003269316A1 (en) 2004-05-04
WO2004032921A1 (en) 2004-04-22
PE20040775A1 (es) 2004-12-10
MA27452A1 (fr) 2005-07-01
TW200424171A (en) 2004-11-16
EP1556034B1 (en) 2008-04-16
MXPA05003866A (es) 2005-06-22
CA2499314A1 (en) 2004-04-22
EP1556034A1 (en) 2005-07-27
DE60320439D1 (de) 2008-05-29

Similar Documents

Publication Publication Date Title
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
PA8604301A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
CY1106894T1 (el) Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων
PA8632801A1 (es) Derivados de tetrahidronaftiridina
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
UY28343A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
UY28150A1 (es) Agentes terapeuticos
UY28721A1 (es) Derivados de sulfonamida para eltratamiento de enfermedades
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
CR7784A (es) Derivados de indol utiles para el tratamiento de enfermedades
DOP2003000732A (es) Derivados de indol utiles para el tratamiento de enfermedades
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
CR7835A (es) Uso de levocetiricina para el tratamiento de la rinitis alergica persistente
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
PA8627101A1 (es) Compuestos para el tratamiento de enfermedades
UY28810A1 (es) Compuestos utiles para el tratamiento de enfermedades
DOP2004000902A (es) Compuestos utiles para el tratamiento de enfermedades
ECSP066700A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2005000037A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2005000041A (es) Compuestos para el tratamientos de enfermandades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades